Twice-yearly HIV shot approved: lenacapavir (Yeztugo)

Published · Researched 2026-09-22

What happened (dated facts)

On June 18, 2025, the U.S. FDA approved Gilead Sciences' Yeztugo (lenacapavir), an injectable HIV-1 capsid inhibitor, as pre-exposure prophylaxis (PrEP) — the first and only twice-yearly PrEP option in the United States, for adults and adolescents weighing at least 35 kg. In the Phase 3 PURPOSE 1 trial, zero HIV infections occurred among 2,134 participants (a 100% reduction), and in PURPOSE 2, 2 infections occurred among 2,179 participants — more than 99.9% of all trial participants remained HIV negative, and the drug was superior to once-daily oral Truvada. The CDC subsequently published clinical recommendations strongly recommending twice-yearly lenacapavir for HIV PrEP (Dear Colleague letter; NYC DOH guidance re-issued Feb 23, 2026), and global access efforts expanded through 2025–2026, including providers preparing to offer it free in some settings (Threads, mpeginitiative, Mar 9, 2026).

Why it is genuinely positive

Two injections a year can do what daily pills often fail to do: overcome adherence and stigma barriers that keep PrEP from the people who need it most. With near-total efficacy in trials, this is the closest the world has come to a practical, scalable tool for ending new HIV infections — and it is already being prescribed, recommended by the CDC, and moving into global access programs.

Social pulse

Circulating on Threads (June 2025 NBC News share by msnownews; March 2026 post by mpeginitiative announcing plans to offer it free) and across health-news web coverage (Drugs.com/HealthDay, WebMD, Contemporary Pediatrics). Observed as celebration of a long-awaited prevention milestone rather than controversy. Instagram curator accounts scanned did not feature it directly.

Verified quotes

• "Yeztugo could be the transformative PrEP option we've been waiting for — offering the potential to boost PrEP uptake and persistence and adding a powerful new tool in our mission to end the HIV epidemic." — Dr. Carlos del Rio, Emory University / Emory Center for AIDS Research, in the FDA approval coverage (Drugs.com/HealthDay, June 20, 2025). Note: statement made in the approval announcement context.
• "This is a historic day in the decades-long fight against HIV. Yeztugo is one of the most important scientific breakthroughs of our time and offers a very real opportunity to help end the HIV epidemic." — Daniel O'Day, Gilead Sciences CEO, company press release via Drugs.com, June 18, 2025. Note: company executive statement in announcement; labeled as such, not organic consensus.

Verification

• Tier: 2
• Primary source: U.S. FDA approval (via Gilead press release, June 18, 2025) + CDC Clinical Recommendations for twice-yearly injectable lenacapavir as HIV PrEP (cdc.gov Dear Colleague letter); NYC Dept. of Health lenacapavir PrEP guidance, Feb 23, 2026. Proves: regulatory approval, trial efficacy numbers, public-health recommendation.
• Social sources: Threads — msnownews (June 19, 2025, shared NBC News FDA approval article); mpeginitiative (March 9, 2026, "We will soon start offering it for free"). Proves: ongoing circulation and real-world access momentum beyond the announcement.
• Positivity check: approved medicine with near-total trial efficacy, publicly recommended, expanding access — tangible human benefit, no reframing needed.

Key facts

UNVERIFIED points

• WHO recommendation of lenacapavir (reported July 2025) was not verified against a primary source this session.
• Science magazine's "2024 Breakthrough of the Year" designation for lenacapavir was not verified this session (prior knowledge; not independently confirmed here).
• Direct Instagram curator posts about lenacapavir were not observed; social layer is Threads + health-press.